Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Hawthorne, New York 10532


Purpose:

The objectives of this study are to evaluate the therapeutic efficacy and safety of DSXS and a Placebo in patients with moderate to severe scalp psoriasis.


Study summary:

This randomized, double-blind, vehicle-controlled, dose-ranging, parallel-group multi-site study is designed to evaluate the therapeutic efficacy and safety of the investigational product, DSXS, for the treatment of moderate to severe scalp psoriasis at different application times up to 30 minutes.


Criteria:

Inclusion Criteria: - Male or non-pregnant, non-lactating females age 12 and older. - Clinical diagnosis of moderate to severe scalp psoriasis, defined by a Investigator's Global Assessment score of at least 3 at screening. Exclusion Criteria: - Under 12 years of age. - Patients whose scalp and/or non-scalp psoriasis necessitates systemic or other concomitant topical therapies during the study. - Has a scalp skin condition that would interfere with the diagnosis or assessment of plaque psoriasis of the scalp.


NCT ID:

NCT02413229


Primary Contact:

Study Director
Natalie Yantovskiy
Taro Pharmaceuticals USA, Inc.


Backup Contact:

N/A


Location Contact:

Hawthorne, New York 10532
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: March 16, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.